Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 29 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2018 This trial has been completed in Bulgaria.